Evidence map›Paper›PMID 31401707›Full record

ArticleCancer causes & control : CCC2019

Type 2 diabetes and obesity in midlife and breast cancer risk in the Reykjavik cohort.

Gertraud Maskarinec, Álfheiður Haraldsdóttir, Kristjana Einarsdóttir, Thor Aspelund, Laufey Tryggvadóttir, Tamara B Harris, Vilmundur Gudnason, Jóhanna E Torfadóttir

Open access · greenAbstract read
In one paragraph

Article in Cancer causes & control : CCC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Gertraud MaskarinecUniversity of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI, 96813, USA. gertraud@cc.hawaii.edu.ORCID http://orcid.org/0000-0002-8129-958X
Álfheiður HaraldsdóttirCentre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Kristjana EinarsdóttirCentre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Thor AspelundCentre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Laufey TryggvadóttirThe Icelandic Cancer Registry, Reykjavik, Iceland.
Tamara B HarrisLaboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Vilmundur GudnasonThe Icelandic Heart Association, Kopavogur, Iceland.
Jóhanna E TorfadóttirCentre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
University of Iceland · ISIcelandic Heart Association · ISNational Institutes of Health · USUniversity of Hawaiʻi at Mānoa · US

Funding

AGES STUDY-THE REYKJAVIK STUDY OF HEALTHY AGING FOR THE NEW MILLENNIUM-26012100N01AG012100 · NIA · ICELANDIC HEART ASSOCIATION · 2002 to 2004
–
Icelandic Centre for Research 152495051NIA NIH HHS N01 AG012100NIA NIH HHS N01-AG-12100
6 · The paper itself

Abstract

purposeAs obesity and type 2 diabetes (T2D) have been increasing worldwide, we investigated their association with breast cancer incidence in the Reykjavik Study.

methodsDuring 1968-1996, approximately 10,000 women (mean age = 53 ± 9 years) completed questionnaires and donated blood samples. T2D status was classified according to self-report (n = 140) and glucose levels (n  = 154) at cohort entry. A linkage with the Icelandic Cancer Registry provided breast cancer incidence through 2015. Cox regression with age as time metric and adjusted for known confounders was applied to obtain hazard ratios (HR) and 95% confidence intervals (CI).

resultsOf 9,606 participants, 294 (3.1%) were classified as T2D cases at cohort entry while 728 (7.8%) women were diagnosed with breast cancer during 28.4 ± 11.6 years of follow-up. No significant association of T2D (HR 0.95; 95% CI 0.56-1.53) with breast cancer incidence was detected except among the small number of women with advanced breast cancer (HR 3.30; 95% CI 1.13-9.62). Breast cancer incidence was elevated among overweight/obese women without (HR 1.18; 95% CI 1.01-1.37) and with T2D (HR 1.35; 95% CI 0.79-2.31). Height also predicted higher breast cancer incidence (HR 1.03; 95% CI 1.02-1.05). All findings were confirmed in women of the AGES-Reykjavik sub-cohort (n  = 3,103) who returned for an exam during 2002-2006. With a 10% T2D prevalence and 93 incident breast cancer cases, the HR for T2D was 1.18 (95% CI 0.62-2.27).

conclusionsThese findings in a population with low T2D incidence suggest that the presence of T2D does not confer additional breast cancer risk and confirm the importance of height and excess body weight as breast cancer risk factors.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCohort StudiesDiabetes Mellitus, Type 2FemaleHumansIcelandIncidenceMiddle AgedOverweightProportional Hazards ModelsRisk FactorsAnthropometryBreast cancerCox regressionObesityProspective cohortType 2 diabetes

Identifiers

PMID31401707
PMCPMC6736708
OpenAlexW2968251779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.